Archives des publications

2016

• Jacques C, Calleja LR, Baud'huin M, Quillard T, Heymann D, Lamoureux F, Ory B. miRNA-193a-5p repression of p73 controls Cisplatin chemoresistance in primary bone tumors. Oncotarget. 2016; 23;7:54503-54514.
• Tellez-Gabriel M, Ory B, Lamoureux F, Heymann MF, Heymann D. Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis. Int J Mol Sci. 2016; 20;17.
• Dumars C, Ngyuen JM, Gaultier A, Lanel R, Corradini N, Gouin F, Heymann D, Heymann MF. Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma. Oncotarget. 2016 29;7:78343-78354.
• Camuzard O, Santucci-Darmanin S, Breuil V, Cros C, Gritsaenko T, Pagnotta S, Cailleteau L, Battaglia S, Panaïa-Ferrari P, Heymann D, Carle GF, Pierrefite-Carle V. Sex-specific autophagy modulation in osteoblastic lineage: a critical function to counteract bone loss in female. Oncotarget. 2016 sous presse
• Chiron D, Bellanger C, Papin A, Tessoulin B, Dousset C, Maiga S, Moreau A, Esbelin J, Trichet V, Chen-Kiang S, Moreau P, Touzeau C, Le Gouill S, Amiot M, Pellat-Deceunynck C. Microenvironment-dependent proliferation and mitochondrial priming loss in mantle cell lymphoma is overcome by anti-CD20. Blood. 2016 sous presse
• Lambert F, Bacevic M, Layrolle P, Schüpbach P, Drion P, Rompen E. Impact of biomaterial microtopography on bone regeneration: comparison of three hydroxyapatites. Clin Oral Implants Res. 2016
• De Seta D, Mancini P, Russo FY, Torres R, Mosnier I, Bensimon JL, De Seta E, Heymann D, Sterkers O, Bernardeschi D, Nguyen Y. 3D curved multiplanar cone beam CT reconstruction for intracochlear position assessment of straight electrodes array. A temporal bone and clinical study. Acta Otorhinolaryngol Ital. 2016; 36:499-505
• Peyrode C, Weber V, Voissière A, Maisonial-Besset A, Vidal A, Auzeloux P, Gaumet V, Borel M, Dauplat MM, Quintana M, Degoul F, Redini F, Chezal JM, Miot-Noirault E. Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept. Mol Cancer Ther. 2016;;15:2575-2585.
• Corradini N, Dagorne L, Retailleau M, Rédini F, Sudour-Bonnange H, Gofti-Laroche L, Le Rhun A, Gaspar N. Which approach of therapeutic education (TE) for adolescents and young adults with cancer? Experience from the TE working group of "Go-AJA".  Bull Cancer. 2016. 103:966-978.
• Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bovée JV, Brennan B, Broto JM, Brugières L, Cleton-Jansen AM, Copland C, Dutour A, Fagioli F, Ferrari S, Fiocco M, Fleuren E, Gaspar N, Gelderblom H, Gerrand C, Gerß J, Gonzato O, van der Graaf W, Hecker-Nolting S, Herrero-Martín D, Klco-Brosius S, Kovar H, Ladenstein R, Lancia C, LeDeley MC, McCabe MG, Metzler M, Myklebost O, Nathrath M, Picci P, Potratz J, Redini F, Richter GH, Reinke D, Rutkowski P, Scotlandi K, Strauss S, Thomas D, Tirado OM, Tirode F, Vassal G, Bielack SS. The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report. Clin Sarcoma Res. 2016 Mar 16;6:3.
• Espitia O, Dréno B, Cassagnau E, Didier Q, Quillard T, Nicol C, Le Bouch Y, Planchon B, Pistorius MA. Exercise-Induced Vasculitis: A Review with Illustrated Cases. Am J Clin Dermatol. 2016;17:635-642. Review.
• Lamora A, Talbot J, Mullard M, Brounais-Le Royer B, Redini F, Verrecchia F. TGF- Signaling in Bone Remodeling and Osteosarcoma Progression. J Clin Med. 2016 3;5. pii: E96. review
• Michel L, Farge D, Baraut J, Marjanovic Z, Jean-Louis F, Porcher R, Grigore EI, Deligny C, Romijn F, Arruda LC, van Pelt J, Levarht N, Verrecchia F, van Laar JM.Evolution of serum cytokine profile after hematopoietic stem cell transplantation in systemic sclerosis patients. Bone Marrow Transplant. 2016;51:1146-9.
• Carapito R, Goldenberg A, Paul N, Pichot A, David A, Hamel A, Dumant-Forest C, Leroux J, Ory B, Isidor B, Bahram S. Protein-altering MYH3 variants are associated with a spectrum of phenotypes extending to spondylocarpotarsal synostosis syndrome. Eur J Hum Genet. 2016;24:1746-1751.
• Guiho R, Biteau K, Grisendi G, Taurelle J, Chatelais M, Gantier M, Heymann D, Dominici M, Redini F. TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models. Int J Cancer. 2016; 139:2802-2811
• Renema N, Navet B, Heymann MF, Lezot F, Heymann D. RANK-RANKL signalling in cancer. Biosci Rep. 2016; 36-4
• Pohin M, Guesdon W, Mekouo AA, Rabeony H, Paris I, Atanassov H, Favot L, Mcheik J, Bernard FX, Richards CD, Amiaud J, Blanchard F, Lecron JC, Morel F, Jégou JF. Oncostatin M overexpression induces skin inflammation but is not required in the mouse model of imiquimod-induced psoriasis-like inflammation.. Eur J Immunol. 2016;46:1737-51
• Brulefert K, Córdova LA, Brulin B, Faucon A, Hulin P, Nedellec S, Gouin F, Passuti N, Ishow E, Heymann D. Pro-osteoclastic In Vitro Effect of Polyethylene-like Nanoparticles: Involvement in the Pathogenesis of Implant Aseptic Loosening. J Biomed Mater Res A. 2016;104:2649-57
• Córdova LA, Guilbaud F, Amiaud J, Battaglia S, Charrier C, Lezot F, Piot B, Redini F, Heymann D. Severe compromise of preosteoblasts in a surgical mouse model of bisphosphonate-associated osteonecrosis of the jaw.. J Craniomaxillofac Surg. 2016;44:1387-94
• Hoornaert A, d'Arros C, Heymann MF, Layrolle P. Biocompatibility, resorption and biofunctionality of a new synthetic biodegradable membrane for guided bone regeneration. Biomed Mater. 2016;10;11:045012.
• Piperno-Neumann S, Le Deley MC, Rédini F, Pacquement H, Marec-Bérard P, Petit P, Brisse H, Lervat C, Gentet JC, Entz-Werlé N, Italiano A, Corradini N, Bompas E, Penel N, Tabone MD, Gomez-Brouchet A, Guinebretière JM, Mascard E, Gouin F, Chevance A, Bonnet N, Blay JY, Brugières L; Sarcoma Group of UNICANCER; French Society of Pediatric Oncology (SFCE); French Sarcoma Group (GSF-GETO). Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016; 17:1070-80
• Gabriel MT, Calleja LR, Chalopin A, Ory B, Heymann D. Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation. Clin Chem. 2016;62:571-81
• Stanovici J, Le Nail LR, Brennan MA, Vidal L, Trichet V, Rosset P, Layrolle P. Bone regeneration strategies with bone marrow stromal cells in orthopaedic surgery.Curr Res Transl Med. 2016;64:83-90. revue
• Tellez-Gabriel M, Brown HK, Young R, Heymann MF, Heymann D. The Challenges of Detecting Circulating Tumor Cells in Sarcoma. Front Oncol. 2016.7;6:202. Revue.
• Baud'huin M, Lamoureux F, Jacques C, Rodriguez Calleja L, Quillard T, Charrier C, Amiaud J, Berreur M, Brounais-LeRoyer B, Owen R, Reilly GC, Bradner JE, Heymann D, Ory B. Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis. Bone. 2016. 23;94:10-21.
• Jacques C, Lamoureux F, Baud'huin M, Calleja LR, Quillard T, Amiaud J, Tirode F, Rédini F, Bradner JE, Heymann D, Ory B. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1. Oncotarget. 2016. 26;7:24125-40
• Ory B, Baud'huin M, Verrecchia F, Brounais-Le Royer B, Quillard T, Amiaud J, Battaglia S, Heymann D, Redini F, Lamoureux F. Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression. Clin Cancer Res. 2016; 15;22:2520-33
• Rodriguez Calleja L, Jacques C, Lamoureux F, Baud'huin M, Tellez Gabriel M, Quillard T, Sahay D, Perrot P, Amiaud J, Charrier C, Brion R, Lecanda F, Verrecchia F, Heymann D, Ellisen LW, Ory B. Np63 Silences a miRNA Program to Aberrantly Initiate a Wound-Healing Program That Promotes TGF-Induced Metastasis. Cancer Res. 2016; 1;76:3236-51
• Flanagan-Steet H, Aarnio M, Kwan B, Guihard P, Petrey A, Haskins M, Blanchard F, Steet R. Cathepsin-Mediated Alterations in TGFß-Related Signaling Underlie Disrupted Cartilage and Bone Maturation Associated With Impaired Lysosomal Targeting. J Bone Miner Res. 2016;31:535-48.
• Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Rédini F, Richter GH, Rossig C, Schadler K, Schäfer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Üren A, Zinovyev A, Delattre O. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget. 2016; 23;7:8613-24
• Boutet MA, Bart G, Penhoat M, Amiaud J, Brulin B, Charrier C, Morel F, Lecron JC, Rolli-Derkinderen M, Bourreille A, Vigne S, Gabay C, Palmer G, Le Goff B, Blanchard F. Distinct expression of interleukin (IL)-36, and , their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease.Clin Exp Immunol. 2016; 184:159-73.
• Biteau K, Guiho R, Chatelais M, Taurelle J, Chesneau J, Corradini N, Heymann D, Redini F. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. Am J Cancer Res. 2016.15;6:677-89.
• Gabriel MT, Calleja LR, Chalopin A, Ory B, Heymann D. Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation.Clin Chem. 2016;62:571-81.
• Davaine JM, Quillard T, Chatelais M, Guilbaud F, Brion R, Guyomarch B, Brennan MÁ, Heymann D, Heymann MF, Gouëffic Y. Bone Like Arterial Calcification in Femoral Atherosclerotic Lesions: Prevalence and Role of Osteoprotegerin and Pericytes. Eur J Vasc Endovasc Surg. 2016;51:259-67.
• Heymann D, Ruiz-Velasco C, Chesneau J, Ratiskol J, Sinquin C, Colliec-Jouault S.Anti-Metastatic Properties of a Marine Bacterial Exopolysaccharide-Based Derivative Designed to Mimic Glycosaminoglycans.  Molecules. 2016. 4;21:309
• Avril P, Duteille F, Ridel P, Heymann M-F, De Pinieux G, Gouin F, Rédini F, Blanchard F, Heymann D, Trichet V, Perrot P. Opposite Effects of Soluble Factors Secreted by Adipose Tissue on Proliferating and Quiescent Osteosarcoma Cells. Plastic and Reconst

• Avril P, Le Nail LR, Brennan MÁ, Rosset P, De Pinieux G, Layrolle P, Heymann D, Perrot P, Trichet V.Mesenchymal stem cells increase proliferation but do not change quiescent state of osteosarcoma cells: Potential implications according to the tumor resection status. J Bone Oncol. 2015 Dec 12;5:5-14.
• Crémet L, Broquet A, Brulin B, Jacqueline C, Dauvergne S, Brion R, Asehnoune K, Corvec S, Heymann D, Caroff N. Pathogenic potential of Escherichia coli clinical strains from orthopedic implant infections towards human osteoblastic cells. Pathog Dis. 2015;73;73:ftv065.
• Arshad MI, Guihard P, Danger Y, Noel G, Le Seyec J, Boutet MA, Richards CD, L'Helgoualc'h A, Genet V, Lucas-Clerc C, Gascan H, Blanchard F, Piquet-Pellorce C, Samson M. Oncostatin M induces IL-33 expression in liver endothelial cells in mice and expands ST2+CD4+ lymphocytes. Am J Physiol Gastrointest Liver Physiol. 2015;309:G542-53.
• Bougault C, Briolay A, Boutet MA, Pilet P, Delplace S, Le Goff B, Guicheux J, Blanchard F, Magne D. Wnt5a is expressed in spondyloarthritis and exerts opposite effects on enthesis and bone in murine organ and cell cultures. Transl Res. 2015;166:627-38.
• Rabeony H, Pohin M, Vasseur P, Petit-Paris I, Jégou JF, Favot L, Frouin E, Boutet MA, Blanchard F, Togbe D, Ryffel B, Bernard FX, Lecron JC, Morel F. IMQ-induced skin inflammation in mice is dependent on IL-1R1 and MyD88 signaling but independent of the NLRP3 inflammasome. Eur J Immunol. 2015; 45:2847-57.
• Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J, Kellokumpu-Lehtinen PL, Lauttia S, Tynninen O, Joensuu H, Heymann D, Määttä JA. Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res. 2015.5;17:101.
• Gama A, Navet B, Vargas JW, Castaneda B, Lézot F. Bone resorption: an actor of dental and periodontal development? Front Physiol. 2015;6:319.2015.00319. Review.
• Quillard T, Araújo HA, Franck G, Shvartz E, Sukhova G, Libby P. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. EurHeart J. 2015;36: 1394-1404.
• Smith MJ, Isidor B, Beetz C, Williams SG,Bhaskar SS, Richer W, O'Sullivan J, Anderson B, Daly SB, Urquhart JE, Fryer A,Rustad CF, Mills SJ, Samii A, du Plessis D, Halliday D, Barbarot S, BourdeautF, Newman WG, Evans DG. Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology. 201513;84:141-7. 
• Rieger E, Dupret-Bories A, Salou L, Metz-Boutigue MH, Layrolle P, Debry C, Lavalle P, Engin Vrana N. Controlled implant/soft tissue interaction by nanoscale surface modifications of 3D porous titanium implants. Nanoscale. 2015;21;7: 9908-18.
• Lamora A, Mullard M, Amiaud J, Brion R, Heymann D, Redini F, Verrecchia F. Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases. Oncotarget. 2015. 10;6:14413-14427.
• Tabareau-Delalande F, Collin C, Gomez-Brouchet A, Bouvier C, Decouvelaere AV, de Muret A, Pagès JC, De Pinieux G. Chromosome 12 long arm rearrangement covering MDM2 and RASAL1 is associated with aggressive craniofacial juvenile ossifying fibroma and extracranial psammomatoid fibro-osseous lesions.. Mod Pathol. 2015; 28:48-56.
• Salou L, Hoornaert A, Stanovici J, Briand S, Louarn G, Layrolle P. Comparative bone tissue integration of nanostructured and microroughened dental implants.. Nanomedicine. 2015;10:741-51. 
• Córdova LA, Trichet V, Escriou V, Rosset P, Amiaud J, Battaglia S, Charrier C, Berreur M, Brion R, Gouin F, Layrolle P, Passuti N, Heymann D. Inhibition of osteolysis and increase of bone formation after local administration of siRNA-targeting RANK in a polyethylene particle-induced osteolysis model.Acta Biomater. 2015;13:150-8
• Salou L, Hoornaert A, Louarn G, Layrolle P. Enhanced osseointegration of titanium implants with nanostructured surfaces: An experimental study in rabbits.Acta Biomater. 2015. 1;11:494-502.
• Carapito R,Paul N, Untrau M, Le Gentil M, Ott L, Alsaleh G, Jochem P, Radosavljevic M, Le Caignec C, David A, Damier P, Isidor B, Bahram S. A de novo ADCY5 mutation causes early-onset autosomal dominant chorea and dystonia. Mov Disord. 2015;30:423-7.
• Ben Arush M, Minard-ColinV, Mosseri V, Defachelles AS, Bergeron C, Algret N, Fasola S, André N, Thebaud E, Corradini N, Bernier V, Martelli H, Ranchère D, Orbach D. Does aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma? Eur J Cancer. 2015; 51:193-201.
• Taieb S, Saada-Bouzid E,Tresch E, Ryckewaert T, Bompas E, Italiano A, Guillemet C, Peugniez C,Piperno-Neumann S, Thyss A, Maynou C, Clisant S, Penel N; French Sarcoma Group. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.. Eur J Cancer. 2015; 201551:202-9.
• Ségaliny AI, Mohamadi A, Dizier B, Lokajczyk A, Brion R, Lanel R, Amiaud J, Charrier C, Boisson-Vidal C, Heymann D. Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer. 2015 1;137:73-85
• Gobin B, Huin MB, Lamoureux F, Ory B, Charrier C, Lanel R, Battaglia S, Redini F, Lezot F, Blanchard F, Heymann D. BYL719, a new -specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma.Int J Cancer. 2015; 15;136:784-96
• Segaliny AI, Brion R, Mortier E, Maillasson M, Cherel M, Jacques Y, Le Goff B, Heymann D. Syndecan-1 regulates the biological activities of interleukin-34. Biochim Biophys Acta. 2015; 4;1853:1010-1021.
• Guihard P, Boutet MA, Brounais-Le Royer B, Gamblin AL, Amiaud J, Renaud A, Berreur M, Rédini F, Heymann D, Layrolle P, Blanchard F. Oncostatin M, an Inflammatory Cytokine Produced by Macrophages, Supports Intramembranous Bone Healing in a Mouse Model of Tibia Injury.. Am J Pathol, 2015.185:765-75
• Vergult S, Dheedene A, Meurs A, Faes F, Isidor B, Janssens S, Gautier A, Le Caignec C,Menten B. Genomic aberrations of the CACNA2D1 gene in three patients with epilepsy and intellectual disability. Eur J Hum Genet. 2015;23:628-32.
• Carapito R, Isidor B,Guerouaz N, Untrau M, Radosavljevic M, Launay E, Cassagnau E, Frenard C, AubertH, Romefort B, Le Caignec C, Ott L, Paul N, Barbarot S, Bahram S. Homozygous IL36RN mutation and NSD1 duplication in a patient with severe pustular psoriasis and symptoms unrelated to deficiency of interleukin-36 receptor antagonist.. Br J Dermatol.2015;172:302-5.
• Knapen M, Gheldof D, Drion P, Layrolle P, Rompen E, Lambert F. Effect of leukocyte- and platelet-rich fibrin (L-PRF) on bone regeneration: a study in rabbits.. Clin Implant Dent Relat Res.2015;17 Suppl 1:e143-52. I
• Lézot F, Chesneau J, Navet B, Gobin B, Amiaud J, Choi Y, Yagita H, Castaneda B, Berdal A, Mueller CG, Rédini F, Heymann D. Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: Mouse strain disparities and synergic effect with zoledronic acid. Bone. 2015;73:51-9.
• Baraut J, Farge D,Jean-Louis F, Masse I, Grigore EI, Arruda LC, Lamartine J, Verrecchia F, Michel L.Transforming growth factor- increases interleukin-13 synthesis via GATA-3 transcription factor in T-lymphocytes from patients with systemic sclerosis.. Arthritis Res Ther. 2015 31;17:196
• Brennan M, Renaud A,Gamblin AL, D'Arros C; Nedellec S, Trichet V, Layrolle P. 3D cell culture and osteogenic differentiation of human bone marrow stromal cells plated onto jet-sprayed or electrospun micro-fiber scaffolds. Biomedical Materials 2015. 4;10:045019.
• Lebouvier A, Poignard A, Cavet M, Amiaud J, Leotot J, Hernigou P, Rahmouni A, Bierling P, Layrolle P, Rouard H, Chevallier N .Development of a simple procedure for the treatment of femoral head osteonecrosis with intra-osseous injection of bone marrow mesenchymal stromal cells: study of their biodistribution in the early time points after injection. Stem Cell Res Ther. 2015.13;6:68
• Ségaliny AI, Brion R, Brulin B, Maillasson M, Charrier C, Téletchéa S, Heymann D. IL-34 and M-CSF form a novel heteromeric cytokine and regulate the M-CSF receptor activation and localization. Cytokine. 2015;76:170-81.
• Guiho R, Biteau K, Heymann D, Redini F. TRAIL-based therapy in pediatric bone tumors: how to overcome resistance. Future Oncol. 2015;11:535-42.
• Pochon C, Martelli H,Mussini C, Pariente D, Heymann MF, Corradini N. Primary Hepatic Ewing Sarcoma With EWS-FLI1 RNA Transcript in a Child.. J Pediatr Hematol Oncol. 2015; 37:411-3.
• Saumet L, Deschamps F, Marec-Berard P, Gaspar N, Corradini N, Petit P, Sirvent N, Brugières L. Radiofrequency ablation of metastases from osteosarcoma in patients under 25 years: the SCFE experience.Pediatr Hematol Oncol. 2015;32:41-9.
• Beranger GE, Djedaini M, Battaglia S, Roux CH, Scheideler M, Heymann D, Amri EZ, Pisani DF. Oxytocin reverses osteoporosis in a sex-dependent manner. Front Endocrinol (Lausanne). 2015. 19;6:81.
• Molin A, Lopez-Cazaux S,Pichon O, Vincent M, Isidor B, Le Caignec C. Patients with isolatedoligo/hypodontia caused by RUNX2 duplication. Am J Med Genet A. 2015;167:1386-90.
• Isidor B, David A. Twogirls with short stature, short neck, vertebral anomalies, Sprengel deformityand intellectual disability. Eur J MedGenet. 2015;58:47-50.
• Lamoureux F & Rédini F. Blocking clusterin inhibits emergence of resistance tozoledronic acid in osteosarcoma. CancerCell & Microenvironment. doi: 10.14800/ccm.438.

• Tabareau-Delalande F, Collin C, Gomez-Bouchet A, Decouvelaere AV, Bouvier C, Larousserie F, Marie B, Delfour C, Aubert S, Rosset P, de Muret A, Pages JC, de Pinieux G. Diagnostic value of investigating GNAS mutations in fibro-osseous lesions: a retrospective study of 91 cases of fibrous dysplasia and 40 other fibro-osseous lesions. Mod. Pathol 2013;26:911-21.

• Carapito R, Paul N, Untrau M, Ott L, Corradini N, Poignant S, Geffroy^ L, Caldagues^ E, Heymann MF, Cassagnau E, Isidor B, Bahram S.A new mutation in the C-SH2 domain of PTPN11 causes Noonan syndrome with multiple giant cell lesions.. *J Human Genet,2013;14. doi: 10.1038/jhg.118

• Castaneda B, Simon Y, Ferbus D, Robert B, Chesneau J, Mueller CG, Berdal A, Lézot F.Role of RANKL (TNFSF11)-Dependent Osteopetrosis in the Dental Phenotype of Msx2 Null Mutant Mice..Plosone 2013. 21;8:e80054. doi: 10.1371

• Gouin F, Dumaine V; the French Sarcoma and Bone Tumor Study Groups (GSF-GETO).Local recurrence after curettage treatment of giant cell tumors in peripheral bones: Retrospective study by the GSF-GETO (French Sarcoma and Bone Tumor Study Groups).Orthop Traumatol Surg Res. 2013.  Oct;99(6 Suppl):S313-8

• Gouëffic Y, Davaine JM, Merlini T, Rimbert A, Hérisson F, Heymann MF, Heymann D, Steenman M, Lambert G.[Arterial heterogeneity]. Rev Med Interne. 2013;34:61-5.

• Davaine JM, Quérat J, Guyomarch B, Brennan MÁ, Costargent A, Chaillou P, Patra P, Gouëffic Y.Incidence and the Clinical Impact of Stent Fractures after Primary Stenting for TASC C and D Femoropopliteal Lesions at 1 Year. Eur J Vasc Endovasc Surg. 2013;46:201-12.

• Brennan MA, Davaine JM, Layrolle P.Pre-vascularization of bone tissue-engineered constructs. Stem Cell Res Ther. 2013. 14;4:96.

• Isidor B, Geffroy L, De Courtivron B, Le Caignec C, T Thiel C, Mortier G, Cormier-Daire V, David A, Toutain A. A new form of severe spondyloepimetaphyseal dysplasia: Clinical and radiological characterization.. American Journal of Medical Genetics. 2013.doi: 10.1002/ajmg.a.36132.

• Odri GA, Padiolleau GB, Gouin FT.Oversized Cups as a Major Risk Factor of Postoperative Pain After Total Hip Arthroplasty.J Arthroplasty. 2013. doi:pii: S0883-5403:00503-2.

• Monderer D, Luseau A, Bellec A, David E, Ponsolle S, Saiagh S, Bercegeay S, Piloquet P, Denis D, Lodé L, Rédini F, Biger M, Heymann D, Heymann MF, Le Bot R, Gouin F, Blanchard F. New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance.. Lab Invest, 2013;93:1100-14.

• Berthelot JM, Le Goff B, Maugars Y.Pathogenesis of hyperostosis: A key role for mesenchymatous cells? Joint Bone Spine. 2013 May 31. doi:pii: S1297-319X:00089-4. 10.1016

• Savoie A, Gouin F, Maugars Y, Isidor B, Larrose C, Berthelot JM. Treatment responses in five patients with ribbing disease including two with 466C>T missense mutations in TGF1.Joint Bone Spine. 2013. doi:pii: S1297-319X:00027-4.

• Rédini F, Odri G, Picarda G, Gaspar N, Heymann MF, Corradini N, Heymann D. Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma? Expert Opin Emerg Drugs,2013 18:339-52.

• Picarda G, Matous E, Amiaud J, Charrier C, Lamoureux f, Heymann MF, Tirode F, Pitard B, Trichet V, Heymann D, F Redini. Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoima by inhibiting RANKL. J Bone Oncol, 2013;doi:10.1016/j.jbo.2013.04.004

• Heymann D, Rédini F. Targeted therapies for bone sarcomas. BoneKey Reports sous presse

• Rousseau J, Gioia R, Layrolle P, Lieubeau B, Heymann D, Rossi A, Marini JC, Trichet V, Forlino A. Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta.. Eur J Human Genet, 2013.doi: 10.1038/ejhg.

• Isidor B, Le Meur G, Conti C, Caldagues E, Lainey E, Launay E, Leclair MD, Le Francois T, Pichon O, Boisseau P, Migraine A, Keren B, Caignec CL, Crow YJ, David A.Exudative retinopathy, cerebral calcifications, duodenal atresia, preaxial polydactyly, micropenis, microcephaly and short stature: A new syndrome?Am J Med Genet A. 2013 Jul 3. doi: 10.1002/ajmg.a.36021

• Baud'huin M, Duplomb L, Teletchea S, Lamoureux F, Ruiz-Velasco C, Maillasson M, Redini F, Heymann MF, Heymann D.Osteoprotegerin: Multiple partners for multiple functions.Cytokine Growth Factor Rev. 2013 Jul 1. doi:pii: S1359-6101:00059-2. 10.1016/j.cytogfr.2013.06.001

• Le Goff B, Berthelot JM, Maugars Y, Heymann D.Osteoclasts in RA: Diverse origins and functions.Joint Bone Spine. 2013;80:586-91. doi: 10.1016/j.jbspin.2013.04.002.

• Miot-Noirault E,  David E, Vidal A, Besse S, Dauplat MM, Gouin F, Heymann D, Rédini F. 99mTc-NTP 15-5 assessment of the early therapeutic response of chondrosarcoma to zoledronic acid in the Swarm rat orthotopic model. European Journal of Nuclear Medicine and Molecular Imaging Research, 2013;20;3:40. doi: 10.1186/2191-219X-3-40.

• Ando K, Heymann MF, Stresing V, Mori K, Rédini F, Heymann D.Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel). 2013; 24;5:591-616. doi: 10.3390/cancers5020591.

• Deschaseaux F, Gaillard J, Langonné A, Chauveau C, Naji A, Bouacida A, Rosset P, Heymann D, De Pinieux G, Rouas-Freiss N, Sensébé L. Regulation and function of immunosuppressive molecule human leukocyte antigen G5 in human bone tissue. FASEB J. 2013;27:2977-87

• Georges S, Chesneau J, Hervouet S, Taurelle J, Gouin F, Redini F, Padrines M, Heymann D, Fortun Y, Verrecchia F.A Disintegrin And Metalloproteinase 12 produced by tumour cells accelerates osteosarcoma tumour progression and associated osteolysis.Eur J Cancer. 2013 doi:pii: S0959-8049:00150-0. 10.1016/j.ejca.2013.02.020.

• Benslimane-Ahmim Z, Poirier F, Delomenie C, Lokajczyk A, Grelac F, Galy-Fauroux I, Mohamedi A, Fischer AM, Heymann D, Lutomski D, Boisson-Vidal C.Mechanistic study of the proangiogenic effect of osteoprotegerin.Angiogenesis. 2013,16:575-93.

• Milan JL, Lavenus S, Pilet P, Louarn G, Wendling S, Heymann D, Layrolle P, Chabrand P. Computational model combined with in vitro experiments to analyse mechanotransduction during mesenchymal stem cell adhesion. Eur Cell Mater. 2013;16;25:97-113.

• Lionetto S, Little A, Moriceau G, Heymann D, Decurtins M, Plecko M, Filgueira L, Cadosch D.Pharmacological blocking of the osteoclastic biocorrosion of surgical stainless steel in vitro.J Biomed Mater Res A.2013, 101:991-997

• Talbot J, Brion R, Picarda G, Amiaud J, Chesneau J, Bougras G, Stresing V, Tirode F, Heymann D, Redini F, Verrecchia FLoss of connexin43 expression in Ewing's sarcoma cells favors the development of the primary tumor and the associated bone osteolysis. BBA - Molecular Basis of Disease.2013;1832:553-64

•  Bussone G, Tamby MC, Calzas C, Kherbeck N, Sahbatou Y, Sanson C, Ghazal K, Dib H, Weksler BB, Broussard C, Verrecchia F, Yaici A, Witko-Sarsat V, Simonneau G, Guillevin L, Humbert M, Mouthon L. IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Ann Rheum Dis. 2012;71:596-605.

• Berthelot JM, De Bandt M, Morel J, Benatig F, Constantin A, Gaudin P, Le Loet X, Maillefert JF, Meyer O, Pham T, Saraux A, Solau-Gervais E, Spitz E, Wendling D, Fautrel B, Guillemin F, STPR group of French Society of Rheumatology;A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: the 'FLARE' instrument. Ann Rheum Dis. 2012;71:1110-6.

• Cassier PA, Fumagalli E, Rutkowski P, Schöffski P, Van Glabbeke M, Debiec-Rychter M, Emile JF, Duffaud F, Martin-Broto J, Landi B, Adenis A, Bertucci F, Bompas E, Bouché O, Leyvraz S, Judson I, Verweij J, Casali P, BlayJY, Hohenberger P; European Organisation for Research and Treatment of Cancer. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumours in the tyrosine kinase inhibitor era. Clin Cancer Res. 2012; 15;18:4458-64.

• Guihard P, Danger Y, Brounais B, David E, Brion R, Delecrin J, Richards CD, Chevalier S, Rédini F, Heymann D, Gascan H, Blanchard F. Induction of Osteogenesis in Mesenchymal Stem Cells by Activated Monocytes/Macrophages Depends on Oncostatin M Signaling. Stem Cells. 2012;30:762-72.

• Minard-Colin V, Ichante JL, Nguyen L, Paci A, Orbach D, Bergeron C, Defachelles AS, André N, Corradini N, Schmitt C, Tabone MD, Blouin P, Sirvent N, Goma G, Geoerger B, Oberlin O. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma - A report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE). Eur J Cancer. 2012; 48:2409-16.

• Geoerger B, Estlin EJ, Aerts I, Kearns P, Gibson B, Corradini N, Doz F, Lardelli P, Miguel BD, Soto A, Prados R, Vassal G. A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) study. Eur J Cancer. 2012; 48:289-96.

• Trichet V, Layrolle P, Escriou V. Lipid nanoparticles for siRNA delivery in lungs. Nanomedicine (Lond). 2012 Feb;7:181-3.

• Lavenus S, Trichet V, Le Chevalier S, Hoornaert A, Louarn G, Layrolle P. Cell differentiation and osseointegration influenced by nanoscale anodized titanium surfaces. Nanomedicine. 2012;7:967-8.

• Hess E, Duheron V, Decossas M, Lézot F, Berdal A, Chea S, Golub R, Bosisio MR, Bridal SL, Choi Y, Yagita H, Mueller CG.RANKL induces organised lymph node growth by stromal cell proliferation. JImmunol.2012;188:1245-54.

• Pautier P, Floquet A, Penel N, Piperno-Neumann S, Isambert N, Rey A, Bompas E, Cioffi A, Delcambre C, Cupissol D, Collin F, Blay JY, Jimenez M, Duffaud F. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer(FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist. 2012;17:1213-20.

• Ray-Coquard I, Italiano A, Bompas E, Le Cesne A, Robin YM, Chevreau C, Bay JO, Bousquet G, Piperno-Neumann S, Isambert N, Lemaitre L, Fournier C, Gauthier E, Collard O, Cupissol D, Clisant S, Blay JY, Penel N; French Sarcoma Group (GSF/GETO). Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist. 2012; 17:260-6.

•  David E, Tirode F, Baud'Huin M, Guihard P, Laud K, Delattre O, Heymann MF, Heymann D, Rédini F, Blanchard F. Oncostatin M Is a Growth Factor for Ewing Sarcoma. Am J Pathol.2012;181:1782-95.

• Picarda G, Surget S, Guiho R, Télétchéa S, Berreur M, Tirode F, Pellat-Deceunynck C, Heymann D, Trichet V, Rédini F. A functional, new short isoform of Death Receptor 4 in Ewing's sarcoma cell lines may be involved in TRAIL sensitivity/resistance mechanisms. Mol Cancer Res. 2012;10:336-46.

• Delaplace M, Lhommet C, De Pinieux G, Vergier B, de Muret A, Machet L. Primary cutaneous Ewing sarcoma: a systematic review focused on treatment and outcome. Br J Dermatol.2012;166:721-6.

• Picarda G, Trichet V, Télétchéa S, Heymann D, Rédini F.TRAIL receptor signaling and therapeutic option in bone tumours: the trap of the bone microenvironment. Am J CancerRes. 2012;45-64.

• Italiano A, Cioffi A, Coco P, Maki RG, Schöffski P, Rutkowski P, Le Cesne A, Duffaud F, Adenis A, Isambert N, Bompas E, Blay JY, Casali P, Keohan ML, Toulmonde M, Antonescu CR, Debiec-Rychter M, Coindre JM, Bui B. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumours (GIST) refractory to first-line imatinib and second-line sunitinib. Ann Surg Oncol. 2012; 19:1551-9.

• Vuillaumier-Barrot S, Isidor B, Dupré T, Le Bizec C, David A, Seta N. Expanding the Spectrum of PMM2-CDG Phenotype. JIMD Rep. 2012;5:123-5.

• Pichard V, Aubert D, Boni S, Battaglia S, Ivacik D, Nguyen TH, Arbuthnot P, Ferry N. Specific micro RNA-regulated TetR-KRAB transcriptional control of transgene expression in viral vector-transduced cells. PLoS One. 2012; 7 :e51952.

• Guyader C, Céraline J, Gravier E, Morin A, Michel S, Erdmann E, de Pinieux G, Cabon F, Bergerat JP, Poupon MF, Oudard S. Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced bytyrosine kinase inhibitors. PLoS One 2012;7:e42252.

• Brullé L, Vandamme M, Riès D, Martel E, Robert E, Lerondel S, Trichet V,  Richard S, Pouvesle JM, Le Pape A. Effects of a Non Thermal Plasma Treatment Alone or in Combination with Gemcitabine in a MIA PaCa2-luc Orthotopic Pancreatic Carcinoma Model. PLoS One. 2012;7:e52653.

• Bouacida A, Rosset P, Trichet V, Guilloton F, Espagnolle N, Cordonier T, Heymann D, Layrolle P, Sensébé L, Deschaseaux F. Pericyte-like progenitors show high immaturity and engraftment potential as compared with mesenchymal stem cells. PLoS One.2012;7:e48648.

• Guillard C, Lintz F, Odri GA, Vogeli D, Colin F, Collon S, Chappard D, Gouin F, Robert H. Effects of graft pretensioning in anterior cruciate ligament reconstruction. Knee Surg Sports Traumatol Arthrosc. 2012; 20:2208-13.

• Peyrode C, Weber V, David E, Vidal A, Auzeloux P, Communal Y, Dauplat MM, Besse S, Gouin F, Heymann D, Chezal JM, Rédini F, Miot-Noirault E. Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies. Invest New Drugs. 2012; 30:178-90.

• Lopes R, Philippeau JM, Passuti N, Gouin F. High rate of ceramic sandwich iner fracture. Clin Orthop Relat Res. 2012;470:1705-10.

• Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Rédini F, Richter GH, Riedmann LT, Rossig C, Schäfer BW, Schwentner R, Scotlandi K, Sorensen PH, Staege MS, Tirode F, Toretsky J, Ventura S, Eggert A, Ladenstein R. The first European interdisciplinary ewing sarcoma research summit. Front Oncol. 2012;2:54.

• Heymann MF, Herisson F, Davaine JM, Charrier C, Battaglia S, Passuti N, Lambert G, Gouëffic Y, Heymann D. Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: Comparison between carotid and femoral beds. Cytokine. 2012;58:300-6. review

• Couec ML, André N, Thebaud E, Minckes O, Rialland X, Corradini N, Aerts I, Bérard PM, Bourdeaut F, Leblond P; on the behalf of the Comité Pharmacologie of the SFCE. Bevacizumab and irinotecan in children with recurrent or refractory brain tumours: Toxicity and efficacy trends. Pediatr Blood Cancer. 2012; 15;59:34-8.

• Schmitt F, Caldari D, Corradini N, Gicquel P, Lutz P, Leclair MD, Podevin G. Tolerance and efficacy of preventive gastrostomy feeding in pediatric oncology. Pediatr Blood Cancer.2012; 59:874-80.

• Bertoncini P, Le Chevalier S, Lavenus S, Layrolle P, Louarn G. Early adhesion of human mesenchymal stem cells on TiO(2) surfaces studied by single-cell force spectroscopy measurements. J Mol Recognit. 2012;25:262-9.

• Bienvenu T, Diebold B, Chelly J, Isidor B. Refining the phenotype associated with MEF2C point mutations. Neurogenetics. 2013;14:71-5.

• Isidor B, Poignant S, Picherot G, Mégabarné A, Quartier P, Bader-Meunier B, Le Caignec C, Le Merrer M, Baujat G, Cormier-Daire V, David A. Progressive polyepiphyseal dysplasia with arthropathy: a distinct disorder from idiopathic juvenile arthritis and pseudorheumatoid dysplasia? Am J Med Genet A. 2012;158A:1754-8.

• Isidor B, Villa O, Pichon O, Briand A, Poulain D, Boisseau P, Pérez-Jurado LA, Le Caignec C. De novo duplication and deletions at 7q in a three-generation family. Am J Med Genet A. 2012;158A:1493-7.

• Strullu M, Rialland F, Cahu X, Brissot E, Corradini N, Thomas C, Blin N, Rialland X, Méchinaud F, Mohty M. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience. Eur J Haematol. 2012; 88:504-9.

• Miot-Noirault E, Gouin F, Dauplat MM, Heymann D, Chezal JM, Rédini F. Relevance of the POS-1 Orthotopic Model As An "Imaging Model" for In Vivo and Simultaneous Monitoring of Tumour Proliferation and Bone Remodeling in Osteosarcoma. Cancer Biother Radiopharm. 2012;27:96-103.

• Eugene T, Corradini N, Carlier T, Dupas B, Leux C, Bodet-Milin C. F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas. Nucl Med Commun. 2012; 33:1089-95.

• Atean I, Pointreau Y, Rosset P, Garaud P, De-Pinieux G, Calais G. Prognostic factors of extremity soft tissue sarcoma in adults. A single institution alanalysis. Cancer Radiother. 2012;16:661-6.

• Lintz F, Moreau A, Odri GA, Waast D, Maillard O, Gouin F. Critical study of resection margins in adult soft-tissue sarcoma surgery. Orthop Traumatol Surg Res. 2012;98:S9-S18

• Bouguennec N, Gouin F, Piétu G. Isolated anterior unilateral sacroiliac dislocation without pubic arch disjunction. Orthop Traumatol Surg Res. 2012;98:359-62.

• Colin F, Lintz F, Bargoin K, Guillard C, Venet G, Tesson A, Gouin F. Aseptic arthritis after ACL reconstruction by Tape Locking Screw (TLS®): report of two cases. Orthop Traumatol Surg Res.2012;98:363-5.

• Baraut J, Farge D, Jean-Louis F, Kesmandt H, Durant C, Verrecchia F, Michel L. [Cytokines in systemic sclerosis]. Pathol Biol (Paris). 2012;60:127-39.

• Lejus C, Desdoits A, Lambert C, Langlois C, Roquilly A, Gouin F, Asehnoune K. Preoperative moderate renal impairment is an independent risk factor of transfusion in elderly patients undergoing hip fracture surgery and receiving glow-molecular-weight heparin for thromboprophylaxis. J Clin Anesth. 2012; 24:378-84.

• Demoor-Goldschmidt C, Minard-Colin V, Cassagneau E, Supiot S, Oberlin O, D'hautuille C, Corradini N. Ameloblastic Fibrosarcoma of the Mandible: Report of 2 Chemosensitive Pediatric Cases.J Pediatr Hematol Oncol. 2012; 34:72-6.

• Geffroy L, Hamel O, Odri GA, Guillard S, Passuti N, Gouin F, Rogez JM, Hamel A. Treatment of an aneurysmal bone cyst of the lumbar spine in children and teenagers, about five cases. J Pediatr Orthop B. 2012;21:269-75.

• Cormier B, Arbion F, Rousselot C, Gaillardin L, de Pinieux G. About a case of rhabdomyosarcoma with an aberrant expression of epithelial markers: a cause ofmisdiagnosis. Ann Pathol. 2012;32:224-8.

• Illac C, Delisle MB, Bonnevialle P, Chiavassa-Gandois H, de Pinieux G, Gomez-Brouchet A. Telangiectatic osteosarcoma secondary to a liposclerosingmyxofibrous tumour: a case report. Ann Pathol.2012;32:259-62.

• Gaspar N, Di Giannatale A, Geoerger B, Rédini F, Corradini N, Enz-Werle N, Tirode F, Marec-Berard P, Gentet JC, Laurence V, Piperno-Neumann S, Oberlin O, Brugieres L. Bone sarcomas: from biology to targeted therapies. Sarcoma. 2012;2012:301975 review

• Duffaud F, Even C, Ray-Coquard I, Bompas E, Khoa-Huynh T, Salas S, Cassier P, Dufresne A, Bonvalot S, Ducimetiere F, Le Cesne A, Blay JY. Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients. Clin Sarcoma Res. 2012; 5;2:11

• Talbot J, Verrecchia F.[Gap junctions and bone remodeling].Biol Aujourdhui. 2012;206:125-34.